Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Omeros Corporation Is Surging Again Today

By Cory Renauer - May 17, 2017 at 12:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Positive trial results for Omeros Corporation's lead candidate keep rolling in.

What happened

The market is pushing up shares of Omeros Corporation (OMER 12.40%) again today. As of 10:50 a.m. EDT on Wednesday, the stock was 11.1% higher after the company reported more encouraging data for its lead rare-disease drug candidate.

So what

Urine protein levels are the latest piece of encouraging news surrounding Omeros Corporation's lead new drug candidate, OMS721 for the treatment of several rare diseases involving kidney function. The novel candidate is currently being tested in a registrational trial intended to support an application for atypical hemolytic uremic syndrome (aHUS), and today's data drop will most likely lead to another registrational trial for the treatment of immunoglobulin A (IgA) nephropathy.

Excited man in front of an upward-sloping chart.

Image source: Getty Images.

Plenty of different conditions can lead to a buildup of IgA in places it shouldn't be. Because the immune system tends to cause permanent kidney damage while cleaning up the mess, one hallmark of kidney damage is increased levels of protein in the urine. This is why the market is pleased with results that show IgA patients excreted 77% less protein after OMS721 treatment.

Now what

Omeros estimates 1 in 1,400 Americans will eventually develop IgA nephropathy, and about 40% of these patients will progress to end-stage renal disease. At the moment there aren't any therapies available for this rare disease, but Soliris from Alexion Pharmaceuticals earned a label expansion for the treatment of aHUS in 2011.

Soliris is one of the world's most expensive therapies, and last year it generated about $2.8 billion in sales for Alexion. If OMS721 eventually earns approvals for aHUS and IgA nephropathy, a peak sales estimate above $1 billion annually seems conservative.

While I'm excited about OMS721, it's not the only reason Omeros is on a list of biotech stocks I'd buy now. The company also boasts an approved drug expected to bring the company to sustainable, positive cash flow while it swings for the fences with its rare-disease candidate.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Omeros Corporation Stock Quote
Omeros Corporation
$2.72 (12.40%) $0.30
Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.